Local
Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), And Coca-Cola (NYSE: KO) Stand Out As Elite Dividend Compounders Built To Last
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Foreign Policy Journal

Abbott Laboratories (NYSE: ABT) made headlines this year after closing a $21 billion cash deal to acquire Exact Sciences, a company focused on cancer diagnostics. The acquisition targets one of Abbott’s slower-growing business units and signals a strategic push to strengthen its diagnostic capabilities in an increasingly competitive healthcare market. Abbott also leads the continuous glucose monitoring space through its FreeStyle Libre franchise, giving it a meaningful foothold in one of medical technology’s fastest-expanding categories. Despite a stretch of mediocre financial results and lingering legal and regulatory headaches, the company’s dividend growth streak remains intact, and analysts see little reason to expect that to change anytime soon. AbbVie (NYSE: ABBV), which was carved out of Abbott as a standalone public company in 2013, has built a compelling track record of its own since then, outperforming the broader market across that span.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Foreign Policy Journal



